$
297.320
-2.460(-0.820%)
  • Overview
  • Forecast
  • Valuation
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
302.990
Open
300.000
VWAP
297.43
Vol
489.79K
Mkt Cap
11.51B
Low
293.920
Amount
145.68M
EV/EBITDA(TTM)
64.68
Total Shares
38.76M
EV
11.25B
EV/OCF(TTM)
62.82
P/S(TTM)
9.55
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
361.11M
+14.45%
1.140
+17.57%
342.06M
+13.63%
0.971
+14.28%
327.28M
+9.31%
0.830
+29.72%
Estimates Revision
The market is revising Downward the revenue expectations for Penumbra, Inc. (PEN) for FY2025, with the revenue forecasts being adjusted by -0.6% over the past three months. During the same period, the stock price has changed by 10.23%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.6%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-3.33%
In Past 3 Month
Stock Price
Go Up
up Image
+10.23%
In Past 3 Month
16 Analyst Rating
up Image
4.10% Upside
Wall Street analysts forecast PEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEN is 309.50 USD with a low forecast of 260.00 USD and a high forecast of 340.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
3 Hold
0 Sell
Strong Buy
up Image
4.10% Upside
Current: 297.320
sliders
Low
260.00
Averages
309.50
High
340.00
Wells Fargo
Larry Biegelsen
Buy
Maintains
$305 → $315
2025-04-24
New
Reason
Stifel
Mathew Blackman
Strong Buy
Maintains
$301 → $318
2025-04-24
New
Reason
Stifel analyst Mathew Blackman raised the firm's price target on Penumbra to $318 from $301 and keeps a Buy rating on the shares. Q1 results were "across-the-board ahead of expectations" and the company re-affirmed or raised key guidance metrics, says the analyst, who sees Penumbra "emerging as a port in stormy waters."
Truist Securities
David Rescott
Strong Buy
Maintains
$315 → $330
2025-04-24
New
Reason
Truist raised the firm's price target on Penumbra to $330 from $315 and keeps a Buy rating on the shares. The company's Q1 revenue outperformance was led by another strong U.S. Thrombectomy performance, while its margin control helped power a solid EPS beat, the analyst tells investors in a research note.
UBS
Priya Sachdeva
Strong Buy
Maintains
$320 → $330
2025-04-24
New
Reason
UBS raised the firm's price target on Penumbra to $330 from $320 and keeps a Buy rating on the shares. Relatively limited macro exposure leaves room for potential upside, the analyst tells investors in a research note.
RBC Capital
Shagun Singh
Buy
Maintains
$315 → $330
2025-04-24
New
Reason
RBC Capital raised the firm's price target on Penumbra to $330 from $315 and keeps an Outperform rating on the shares. The company delivered a Q1 beat, and maintained 2025 guidance despite China headwinds and given its recent guidance philosophy of conservatism, the analyst tells investors in a research note. Penumbra's business momentum is robust as it posted solid high-teens underlying growth in Q1 ex-China, the firm adds.
Truist Securities
David Rescott
Strong Buy
Maintains
$325 → $315
2025-04-11
Reason
Truist analyst Richard Newitter lowered the firm's price target on Penumbra to $315 from $325 and keeps a Buy rating on the shares as part of a broad research note previewing Q1 results in Medical Technology. The group's revenue and earnings are less at risk than it could be for a number of other sub-sectors, which will likely keep investors relatively interested in the space even with some tariff choppiness in the backdrop, though the firm is also bracing for cautious 2025 outlooks as companies and models will likely begin to dial-in some macro uncertainty, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Penumbra Inc (PEN.N) is 75.26, compared to its 5-year average forward P/E of 274.50. For a more detailed relative valuation and DCF analysis to assess Penumbra Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
274.50
Current PE
75.26
Overvalued PE
556.50
Undervalued PE
-7.50

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
111.98
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
176.13
Undervalued EV/EBITDA
47.84

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
9.38
Current PS
0.00
Overvalued PS
12.09
Undervalued PS
6.67

Financials

Annual
Quarterly
FY2025Q1
YoY :
+16.32%
324.14M
Total Revenue
FY2025Q1
YoY :
+233.44%
40.35M
Operating Profit
FY2025Q1
YoY :
+256.51%
39.22M
Net Income after Tax
FY2025Q1
YoY :
+257.14%
1.00
EPS - Diluted
FY2025Q1
YoY :
+9.34%
35.50M
Free Cash Flow
FY2025Q1
YoY :
+2.46%
66.60
Gross Profit Margin - %
FY2025Q1
YoY :
+26.12%
12.12
FCF Margin - %
FY2025Q1
YoY :
+206.33%
12.10
Net Margin - %
FY2025Q1
YoY :
-58.28%
3.50
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
41.5M
USD
17
3-6
Months
8.2M
USD
8
6-9
Months
12.7M
USD
10
0-12
Months
6.4M
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
177.6K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
166.6K
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
5
184.3K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
8
276.9K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

PEN News & Events

Events Timeline

2025-04-23 (ET)
2025-04-23
16:29:02
Penumbra backs FY25 revenue $1.34B-$1.36B, consensus $1.35B
select
2025-04-23
16:28:22
Penumbra reports Q1 EPS $1.00, consensus 67c
select
2025-02-18 (ET)
2025-02-18
16:09:55
Penumbra sees FY25 revenue $1.34B-$1.36B, consensus $1.36B
select
Sign Up For More Events

News

9.5
04-24Benzinga
Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst
9.5
04-23PRnewswire
Penumbra, Inc. Reports First Quarter 2025 Financial Results
7.0
04-21Globenewswire
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Penumbra, Inc. (NYSE: PEN) and Encourages Current Penumbra Shareholders to Contact the Firm
Sign Up For More News

FAQ

arrow icon

What is Penumbra Inc (PEN) stock price today?

The current price of PEN is 297.32 USD — it has decreased -0.82 % in the last trading day.

arrow icon

What is Penumbra Inc (PEN)'s business?

arrow icon

What is the price predicton of PEN Stock?

arrow icon

What is Penumbra Inc (PEN)'s revenue for the last quarter?

arrow icon

What is Penumbra Inc (PEN)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Penumbra Inc (PEN)'s fundamentals?

arrow icon

How many employees does Penumbra Inc (PEN). have?

arrow icon

What is Penumbra Inc (PEN) market cap?